Skip to main content
Clinical Trials/NCT02492243
NCT02492243
Completed
Phase 2

Continuous Rhythm Monitoring in Patients After Acute Myocardial infaRction and pREServed Left venTricle Ejection Fraction

Meshalkin Research Institute of Pathology of Circulation1 site in 1 country50 target enrollmentAugust 2011

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Myocardial Infarction
Sponsor
Meshalkin Research Institute of Pathology of Circulation
Enrollment
50
Locations
1
Primary Endpoint
Ventricular fibrillation
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The trial will inform whether detection of ventricular arrhythmias by means of implantable loop recorder (ILR) can help to predict SCD in the large population of survivors of a myocardial infarction with preserved left ventricular function, EF>40%. This may improve risk stratification in these patients, and can inform on the clinical use of subcutaneous monitors to identify post-infarction populations in need for an intervention to prevent sudden death.

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
June 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Meshalkin Research Institute of Pathology of Circulation
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Ventricular fibrillation

Time Frame: 24 months

Cardiac arrest

Time Frame: 24 months

Documented Arrhythmic death without evidence of primary non cardiac cause

Time Frame: 24 months

Sustained, nonsustained, symptomatic, asymptomatic ventricular tachycardias

Time Frame: 24 months

Atrial Fibrillation (symptomatic and asymptomatic)

Time Frame: 24 months

Secondary Outcomes

  • Changing in treatment strategy, based on physician decision(24 months)
  • CV events(24 months)
  • Invasive procedures for arrhythmia treatment(24 months)
  • All Arrhythmic events recorded by ILR(24 months)
  • Changing in medical treatment (anticoagulation, antiarrhythmic drugs)(24 months)

Study Sites (1)

Loading locations...

Similar Trials